Older patients (>65 years) with HFrEF treated with sacubitril/valsartan had a significantly higher mortality rate compared to younger patients (14.5% vs 2.0%; P=0.04).
Cohort (n=127)
Does age >65 years worsen outcomes and increase side effects in patients with chronic heart failure with reduced ejection fraction treated with sacubitril/valsartan compared to age ≤65 years?
In HFrEF patients treated with sacubitril/valsartan, older age (>65 years) is associated with higher mortality and more side effects compared to younger patients, though ventricular arrhythmia incidence is similar.
Absolute Event Rate: 14.5% vs 2%
p-value: p=0.04
The treatment with sacubitril/valsartan in patients suffering from chronic heart failure with reduced ejection fraction increases left ventricular ejection fraction and decreases the risk of sudden cardiac death. We conducted a retrospective analysis regarding the impact of age differences on the treatment outcome of sacubitril/valsartan in patients with chronic heart failure with reduced ejection fraction. Patients were defined as adults if ≤65 years (n = 51) and older if >65 years of age (n = 76). The incidence of ventricular arrhythmias at 1-year follow-up was comparable in both groups (30.8 vs 26.5%; p = 0.71). The mortality rate in adult patients is significantly lower as compared with older patients (2 vs 14.5%; log-rank = 0.04). Older patients may suffer remarkably more side effects than adult patients (21.1 vs 11.8%; p = 0.03).
Abumayyaleh et al. (Thu,) conducted a cohort in Chronic heart failure with reduced ejection fraction (n=127). Age >65 years vs. Age ≤65 years was evaluated on Mortality rate (p=0.04). Older patients (>65 years) with HFrEF treated with sacubitril/valsartan had a significantly higher mortality rate compared to younger patients (14.5% vs 2.0%; P=0.04).